Thoracic Paravertebral Block for Postoperative Pain Management After VATS

NCT ID: NCT06689358

Last Updated: 2024-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-01

Study Completion Date

2024-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized controlled trial evaluated the efficacy of a thoracic paravertebral block (TPVB) in reducing opioid requirements and pain intensity in the PACU after video-assisted thoracoscopic surgery (VATS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This randomized controlled trial evaluated the efficacy of a thoracic paravertebral block (TPVB) in reducing opioid requirements and pain intensity in the PACU after video-assisted thoracoscopic surgery (VATS). Adult patients scheduled for elective VATS who meet the eligibility criteria will be randomized to either Arm:

Arm 1: General anesthesia with TPVB;

Arm 2: General anesthesia alone (control group).

Primary Outcome: to assess Opioid requirement in the PACU

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Arm 1: General anesthesia with TPVB; Type: Experimental Intervention: 0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space.

Arm 2: General anesthesia alone (control group). Type: No intervention (control) Intervention: No intervention
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

General anesthesia with TPVB

0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space

Group Type EXPERIMENTAL

0.4 ml/kg of 0.5% bupivacaine

Intervention Type DRUG

0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space

General anesthesia alone (control group).

General anesthesia SOC alone

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.4 ml/kg of 0.5% bupivacaine

0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients scheduled for elective VATS, ASA physical status II-III, BMI 19-40.

Exclusion Criteria

* Patient refusal, coagulation disorders, contraindications to TPVB, chronic analgesic use, mental illness
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King Hussein Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahed Al-Edwan, MD

Role: PRINCIPAL_INVESTIGATOR

KHCC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

King Hussein Cancer Center

Amman, , Jordan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Jordan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22 KHCC 158

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Paravertebral Catheters for VATS Procedures
NCT02361775 COMPLETED EARLY_PHASE1
Paravertebral Calcitonin in Thoracotomy
NCT06330168 ACTIVE_NOT_RECRUITING NA